Top 15 Companies in Global Rapid Acting Insulin Market (2024–2035): Competitive Analysis and Forecast

Description

According to a research report published by Spherical Insights & Consulting, The Global Rapid-Acting Insulin Market Size is projected to grow from USD 4.32 Billion in 2024 to USD 12.04 Billion by 2035, at a CAGR of 9.77% during the forecast period 2024–2035. The global rapid-acting insulin market is driven by rising diabetes prevalence, increasing adoption of insulin analogs, growing awareness of glycemic control, and advancements in drug delivery devices. Expanding healthcare access, supportive reimbursement policies, and demand for fast-acting therapies to manage postprandial glucose levels further accelerate market growth worldwide.

 

Introduction

The global rapid acting insulin market encompasses fast-acting insulin analogs such as lispro, aspart, and glulisine, designed to regulate postprandial blood glucose levels in individuals with diabetes. These formulations have a rapid onset of action and are commonly utilized in the treatment of both Type 1 and advanced Type 2 diabetes. Rapid-acting insulin is specifically administered to control blood sugar surges that occur immediately after meals. It typically begins to take effect within 5 to 15 minutes, reaches peak activity between 1 and 3 hours, and maintains its effect for approximately 2 to 5 hours. The market is expanding steadily due to the growing disease burden and evolving treatment approaches. A major driving factor is the sharp rise in diabetes prevalence, with the World Health Organization estimating about 830 million people living with diabetes globally, many lacking access to adequate treatments. Increasing adoption of insulin analogs, advanced delivery systems like pumps, and greater awareness of glycemic control are further accelerating demand. Opportunities exist in biosimilar insulin development, emerging markets, and digital diabetes care integration. Recent developments highlight strong momentum, as the WHO added rapid-acting insulin analogues to its Essential Medicines List in 2025 to improve global access. Additionally, innovations such as glucose-responsive smart insulin are being explored, indicating future growth potential.

 

 News:

•  In February 2025, the U.S. Food and Drug Administration approved Merilog (insulin aspart biosimilar), marking the first rapid-acting insulin biosimilar and expanding cost-effective treatment options.

 

• In December 2024, Novo Nordisk announced substantial price reductions for its insulin products, reflecting increasing efforts to enhance affordability and patient access.

 

• In October 2024, A proposal was submitted to the World Health Organization to include rapid-acting insulin analogues in the Essential Medicines List, aiming to broaden global availability.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Rapid-Acting Insulin Market.

 

Market Segmentation

Global Rapid Acting Insulin Market Size, Share, and, By Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), By Indication (Type 1 Diabetes and Type 2 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores), By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa), Analysis and Forecast 2024 – 2035.

 

Global Rapid Acting Insulin Market Size & Statistics

• The market size for Global Rapid Acting Insulin was estimated to be worth USD 4.32 Billion in 2024.
• The market is going to expand at a CAGR of 9.77% between 2024 and 2035.
• The Global Rapid-Acting Insulin market size is anticipated to reach USD 12.04 Billion by 2035.
• North America is expected to generate the largest revenue during the forecast period in the Global Rapid-Acting Insulin market
• Asia Pacific is expected to grow at the fastest rate during the forecast period in the Global Rapid-Acting Insulin market.

 

Regional growth and demand              

Asia Pacific is expected to grow at the fastest rate during the forecast period in the global rapid-acting insulin market. Asia Pacific is expected to grow at the fastest rate due to the rapidly increasing diabetes population, particularly in countries such as India and China. Expanding healthcare infrastructure, rising urbanization, and improving access to insulin therapies are key growth drivers. Additionally, growing awareness of early diabetes management and increasing healthcare expenditure are accelerating adoption of rapid-acting insulin across emerging economies.

 

North America is expected to generate the largest revenue during the forecast period in the global rapid-acting insulin market. North America is expected to generate the highest revenue due to advanced healthcare systems, high diagnosis rates, and strong adoption of insulin analogs. Favorable reimbursement frameworks, continuous technological advancements in insulin delivery devices, and the presence of major pharmaceutical companies further support its leading market share.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Rapid-Acting Insulin Market.

 

 

Top 10 Trends in the Global Rapid-Acting Insulin Market

• Rising adoption of insulin analogs over conventional insulin
• Growth of biosimilar rapid-acting insulin products
• Increasing integration of insulin pumps and smart delivery devices
• Expansion of digital diabetes management platforms
• Rising demand in emerging economies
• Advancements in ultra-fast acting insulin formulations
• Strategic pricing initiatives to improve affordability
• Growing role of telehealth in diabetes care
• Increased focus on personalized treatment approaches
• Regulatory support for improved insulin accessibility

 

1. Rising adoption of insulin analogs over conventional insulin

The global rapid-acting insulin market is witnessing a steady shift from conventional human insulin to insulin analogs due to their improved pharmacokinetic profiles and enhanced patient outcomes. Rapid-acting analogs provide faster onset and better postprandial glucose control, reducing the risk of hypoglycemia compared to traditional insulin formulations. Healthcare providers increasingly recommend analogs as part of intensive insulin therapy, particularly for Type 1 diabetes management. Growing clinical evidence supporting their efficacy and safety further drives adoption. Additionally, patient preference for flexible dosing schedules and improved quality of life contributes to the increasing reliance on insulin analogs across both developed and developing healthcare systems.

 

2. Growth of biosimilar rapid-acting insulin products

The emergence of biosimilar rapid-acting insulin products is transforming the competitive landscape by introducing cost-effective alternatives to branded insulin analogs. Biosimilars are gaining traction as regulatory agencies streamline approval pathways to enhance accessibility and affordability. These products maintain comparable safety, efficacy, and quality standards, encouraging their adoption among healthcare providers and patients. Pharmaceutical companies are increasingly investing in biosimilar development to capture untapped market potential, especially in price-sensitive regions. The growing availability of biosimilars is expected to intensify competition, reduce treatment costs, and expand patient access to insulin therapy, thereby supporting overall market growth and sustainability.

 

3. vIncreasing integration of insulin pumps and smart delivery devices

Technological advancements in insulin delivery systems are significantly influencing the rapid-acting insulin market. The integration of insulin pumps, continuous glucose monitoring systems, and smart pens enables precise dosing and real-time glucose tracking. These innovations improve glycemic control while minimizing human error associated with manual administration. Automated insulin delivery systems, often referred to as closed-loop or artificial pancreas systems, are gaining clinical acceptance. Their compatibility with rapid-acting insulin enhances therapeutic outcomes. As healthcare systems increasingly adopt digital health solutions, the demand for advanced insulin delivery devices continues to grow, supporting better disease management and driving innovation in the global market.

 

4. Expansion of digital diabetes management platforms

The expansion of digital diabetes management platforms is reshaping how patients and healthcare providers monitor and manage blood glucose levels. Mobile applications, cloud-based analytics, and remote monitoring tools enable continuous tracking and data-driven decision-making. These platforms often integrate with insulin delivery devices, offering personalized insights and improving adherence to treatment regimens. The growing use of telemedicine further enhances patient engagement and access to specialized care. Digital health solutions are particularly valuable in managing chronic conditions such as diabetes, where consistent monitoring is essential. As digital infrastructure improves globally, these platforms are expected to play an increasingly central role in diabetes care.

 

5. Rising demand in emerging economies

Emerging economies are becoming key growth drivers in the global rapid-acting insulin market due to increasing diabetes prevalence and improving healthcare access. Countries in Asia-Pacific, Latin America, and parts of Africa are witnessing a surge in lifestyle-related diseases, leading to higher demand for effective diabetes treatments. Government initiatives to strengthen healthcare infrastructure and expand insurance coverage are facilitating greater access to insulin therapies. Additionally, rising awareness about early diagnosis and disease management is encouraging treatment adoption. Pharmaceutical companies are actively expanding their presence in these regions through partnerships and localized production, further accelerating market growth and improving treatment accessibility.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the global rapid acting insulin market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Rapid-Acting Insulin Market.

 

Top 15 Companies Leading the Global Rapid Acting Insulin Market

1. Novo Nordisk
2. Eli Lilly and Company
3. Sanofi
4. Biocon Biologics
5. Gan & Lee Pharmaceuticals
6. Wockhardt
7. MannKind Corporation
8. Tonghua Dongbao Pharmaceutical
9. Viatris
10. Julphar
11. The United Laboratories
12. Geropharm
13. Ypsomed Holding AG
14. Adocia
15. Arecor Therapeutics

 

1. Novo Nordisk

Headquarters: Bagsværd, Denmark

Novo Nordisk, active in over 170 countries, is a global leader in diabetes care and a dominant player in rapid-acting insulin. The company develops and markets advanced insulin analogs such as NovoRapid/NovoLog and Fiasp, widely used for effective postprandial glucose control. It maintains a strong global presence through continuous innovation in insulin formulations and delivery systems, including smart pens. The company focuses on improving accessibility and patient outcomes by expanding manufacturing capabilities and strengthening distribution networks. Its commitment to research and patient-centric solutions reinforces its leadership in the global rapid-acting insulin market.

 

2. Eli Lilly and Company

Headquarters: Indianapolis, Indiana, USA

Eli Lilly and Company, active in over 120 countries, is a key competitor in the global rapid-acting insulin market. The company offers widely recognized products such as Humalog and Lyumjev, designed for rapid glucose control. It emphasizes innovation in insulin delivery through connected devices and smart pen technologies. Lilly’s global strategy includes expanding access to insulin therapies and enhancing affordability initiatives. The company continues to strengthen its position through research-driven advancements and strategic collaborations. Its strong commercial footprint and focus on next-generation insulin solutions support its significant role in addressing the growing global diabetes burden.

 

3. Sanofi

Headquarters: Paris, France

Sanofi, active in more than 100 countries, is a major participant in the global insulin market, including rapid-acting insulin segments. The company manufactures insulin glulisine under the brand Apidra and offers biosimilar options such as Admelog. It focuses on delivering accessible diabetes treatments through global partnerships and diversified product portfolios. Sanofi leverages its strong distribution capabilities and established healthcare networks to maintain market presence. The company continues to invest in research and development to enhance insulin formulations and improve patient outcomes, supporting its ongoing contribution to diabetes management worldwide.

 

4. Biocon Biologics

Headquarters: Bengaluru, India

Biocon Biologics, active in over 120 countries, is a leading biosimilar insulin manufacturer with a growing footprint in the rapid-acting insulin market. The company focuses on developing and commercializing cost-effective insulin analogs, including biosimilar versions of insulin aspart and lispro. It plays a critical role in expanding access to affordable diabetes care, particularly in emerging markets. Through global partnerships and regulatory approvals across key regions, Biocon Biologics continues to strengthen its presence. Its emphasis on innovation, large-scale manufacturing, and accessibility supports its rising influence in the global insulin landscape.

 

5. Gan & Lee Pharmaceuticals

Headquarters: Beijing, China

Gan & Lee Pharmaceuticals, active in over 30 countries, is a significant player in the rapid-acting insulin segment, particularly within Asia. The company produces insulin analogs such as Prandilin, which is widely used for managing post-meal glucose levels. It focuses on expanding its international presence through regulatory approvals and partnerships in emerging and developed markets. Gan & Lee invests in research and development to enhance insulin formulations and delivery efficiency. Its growing export activities and strong domestic leadership position it as an important contributor to the global rapid-acting insulin market.

 

Are you ready to discover more about the global rapid acting insulin market?

The report provides an in-depth analysis of the leading companies operating in the global rapid acting insulin market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Rapid-Acting Insulin Market.

 

Company Profiles

1. Novo Nordisk

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisition
• SWOT Analysis

1. Eli Lilly and Company
2. Sanofi
3. Biocon Biologics
4. Gan & Lee Pharmaceuticals
5. Wockhardt
6. MannKind Corporation
7. Tonghua Dongbao Pharmaceutical
8. Viatris
9. Others.

 

Our Reports

https://www.sphericalinsights.com/reports/europe-anti-aging-supplements-market
https://www.sphericalinsights.com/reports/europe-ophthalmic-drugs-market
https://www.sphericalinsights.com/reports/europe-methanol-market
https://www.sphericalinsights.com/reports/germany-asphalt-pavers-market
https://www.sphericalinsights.com/reports/france-fertility-services-market

 

Conclusion

The global rapid-acting insulin market is positioned for sustained growth, driven by the rising global burden of diabetes, increasing adoption of insulin analogs, and continuous advancements in drug delivery technologies. As highlighted, the market is evolving with strong momentum supported by biosimilar development, digital diabetes management, and expanding access in emerging economies. Leading companies such as Novo Nordisk, Eli Lilly and Company, and Sanofi continue to strengthen their positions through innovation and global expansion strategies. Additionally, supportive regulatory initiatives and growing awareness of glycemic control are enhancing treatment accessibility. With Asia-Pacific emerging as the fastest-growing region and North America maintaining market dominance, the competitive landscape is expected to intensify. Overall, the market presents significant opportunities for stakeholders focusing on affordability, innovation, and patient-centric solutions.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter